trending Market Intelligence /marketintelligence/en/news-insights/trending/cC61tdKdSeQHecn1F2WBAA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

European Patent Office upholds FibroGen patent for anemia treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


European Patent Office upholds FibroGen patent for anemia treatment

The European Patent Office upheld FibroGen Inc.'s patent for small molecule inhibitors meant to treat iron deficiency.

The patent covers inhibitors of hypoxia-inducible factor prolyl hydroxylase, an enzyme that allows cells to respond to low oxygen concentrations.

The patent was challenged by Akebia Therapeutics Inc., Bayer Intellectual Property GmbH, Bayer Pharma AG and Bayer Animal Health GmbH. Another patent claim from Glaxo Group Ltd. was deemed invalidly filed.

The European Patent Office also handed down a decision against FibroGen in a related patent challenge from the same parties. FibroGen has appealed the decision and expects a resolution in three to four years.

FibroGen is conducting global phase 3 clinical trials for its Roxadustat small molecule inhibitor.